Hayashi Hidetoshi

ハヤシヒデトシ | Hayashi Hidetoshi

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (5)： Cancer of Unknown Primary , Lung Cancer , Gene analysis , medical oncology , immune checkpoint inhibitor

Research theme for competitive and other funds (5)：

2023 - 2026 Validation study of a model to estimate the primary organ of cancer of unknown primary
2022 - 2025 Analysis of the risk factors for the development and severity of immune-related adverse events by immune checkpoint inhibitors
2019 - 2022 Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.
2016 - 2018 Resistance mechanis of molecular targeted therapy and tumor micro environment as the immune-checkpoint inhibitor's biomarker
2014 - 2017 未治療原発不明癌に対する次世代シークエンスを用いた原発巣推定に基づく治療効果の意義を問う第 II 相試験

Papers (281)：

Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. Journal of Clinical Investigation. 2024
Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa, Yoshimasa Shiraishi, Ryota Saito, Junko Tanizaki, Yosuke Tamura, Akito Hata, Kosuke Tsuruno, et al. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer. British journal of cancer. 2024
Satoru Hagiwara, Junko Tanizaki, Hidetoshi Hayashi, Yoriaki Komeda, Naoshi Nishida, Akihiro Yoshida, Tomoki Yamamoto, Takuya Matsubara, Masatoshi Kudo. Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy. Cancer reports (Hoboken, N.J.). 2024. e1960
Junko Tanizaki, Hidetoshi Hayashi. Unraveling Pseudo Kidney Injury: The Significance of Understanding Our “MATE” in Molecular-Targeted Therapies. Journal of Thoracic Oncology. 2024
Yoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, Hideaki Mizutani, Haruko Daga, Koichi Azuma, Hirotaka Matsumoto, Osamu Hataji, Kazumi Nishino, Masahide Mori, et al. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA oncology. 2023

ｍore...

MISC (249)：

金村宙昌, 竹原俊幸, 小野寺勇太, 寺村岳士, 鈴木慎一郎, 坂井和子, 西尾和人, 中川和彦, 林秀敏, 米阪仁雄. PTPRRを介したEGFR活性化に起因するKRASG12C阻害薬耐性の克服(Combating acquired resistance to KRAS inhibitors in NSCLC by targeting PTPRR-mediated activation of EGFR signaling). 日本癌学会総会記事. 2023. 82回. 422-422
米阪仁雄, 稲垣千昌, 稲垣千昌, 高濱隆幸, 高濱隆幸, 白石直樹, 磯本晃佑, 金村宙昌, 鈴木慎一郎, 谷崎潤子, et al. Providing Anti-Lung Cancer Drug Therapy Based on Genetic Information by Comprehensive Genomic Profiling. 日本癌学会学術総会抄録集(Web). 2023. 82nd
村田修一, 谷崎潤子, 岩朝勤, 黒崎隆, 田中薫, 林秀敏, 中川和彦, 濱有一郎. ニボルマブ+イピリムマブ併用療法中に敗血症との鑑別を要する免疫関連下垂体炎を発症した肺腺癌の1例. 肺癌(Web). 2023. 63. 3
磯本晃佑, 原谷浩司, 田中薫, 谷崎潤子, 高濱隆幸, 金村宙昌, 鈴木慎一郎, 林秀敏. 腫瘍微小環境における免疫細胞の局在と免疫チェックポイント阻害薬の効果との関連. 日本肺癌学会学術集会号. 2023. 64th (CD-ROM)
川中雄介, 田中薫, 須田健一, 高濱隆幸, 林秀敏. 原発不明癌に対するニボルマブ治療中に肺サルコイド様肉芽腫変化をきたした一例. 日本肺癌学会学術集会号. 2023. 64th (CD-ROM)

ｍore...

Patents (2)：

Lectures and oral presentations (4)：

Prognostic impact of EMT-related genes on post-operative prognosis in hepatocellular carcinoma.
(AACR 103rd Annual Meeting 2011 2012)
進行肺腺癌を対象としたゲフィチニブ/S-1併用療法第1層臨床試験
(第51回日本肺癌学会総会 2010)
進行肺腺癌を対象としたゲフェチニブ/S-1 併用療法第1相臨床試験
(第92回日本肺癌学会関西支部会 2010)
ソラフェニブは肺癌細胞においてKRAS野生型に対しては
(第8回日本臨床腫瘍学会総会 2010)

Education (2)：

2009 - 2012 Kindai University Faculty of Medicine
1997 - 2003 Osaka University Faculty of Medicine Medical School

Professional career (1)：

医学博士 (近畿大学)

Work history (9)：

2023/04 - 現在 Kindai University, Faculty of Medicine Department of Medical Oncology Professor
2022/04 - 現在 Kindai University, Faculty of Medicine Department of Medical Oncology
2020/04 - 2022/03 近畿大学医学部内科学腫瘍内科講師
2015/10 - 2020/03 Kindai university hospital Department of Medical Oncology Lecturer
2015/04 - 2015/09 Kindai university hospital Department of Medical Oncology Assistant professor

Show all

Committee career (7)：

2022/03 - 現在 Japanese Society of Medical Oncology Vice chair of the Specialist Examination Subcommittee
2020/02 - 現在 International Association for the Study of Lung Cancer Membership committee
2017 - 現在日本臨床腫瘍学会学術集会部会委員
2017 - 現在日本がん治療認定医機構教育委員会専門部会委員
2020/10 - 日本肺癌学会データベース委員会委員

Show all

Awards (3)：

2022/12 - 日本肺癌学会篠井・河合賞
2015/07 - 日本臨床腫瘍学会日本臨床腫瘍学会奨励賞
2008/06 - 西日本がん研究機構西日本がん研究機構賞

Association Membership(s) (5)：

American Society of Clinical Oncology , 日本臨床腫瘍学会 , THE JAPAN LUNG CANCER SOCIETY , THE JAPANESE SOCIETY OF INTERNAL MEDICINE , International Association for the Study of Lung Cancer

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page